MODY 1(HNF4A突变)与MODY 5(HNF1B突变)的频率与特征:DPV数据库分析
基于DPV多国注册数据库,纳入44例HNF4A-MODY和35例HNF1B-MODY患者,与20岁以下1型或2型糖尿病患者比较。两种MODY诊断年龄显著大于1型糖尿病,HNF4A-MODY诊断时C肽高于1型糖尿病,糖化血红蛋白低于1型糖尿病,但38%患者最初被误分类为1型或2型糖尿病。
要点
- HNF4A与HNF1B-MODY诊断年龄显著大于1型糖尿病。
- HNF4A-MODY诊断时C肽高于1型糖尿病。
- 38%的MODY患者最初被误分类为1型或2型糖尿病。
核心结论
- DPV注册库可精确刻画HNF4A-MODY和HNF1B-MODY的表型与治疗,但38%患者最初被误分类为1型或2型糖尿病。
研究设计与样本
- 在DPV注册库中纳入44例HNF4A-MODY和35例HNF1B-MODY患者,与20岁以下1型或2型糖尿病患者比较。
主要发现
- HNF4A-MODY和HNF1B-MODY诊断年龄分别为13.8岁和13.5岁,均显著大于1型糖尿病的8.8岁(P<0.0001)。
- HNF4A-MODY诊断时平均C肽为1.8 ng/mL,高于1型糖尿病的0.9 ng/mL(P<0.01)。
- 36.4%的HNF4A-MODY和65.7%的HNF1B-MODY患者使用胰岛素治疗,仅20.5%和8.6%单用口服降糖药(分别P<0.05和P<0.01 vs 2型糖尿病)。
- 最近一次随访时HNF4A-MODY和HNF1B-MODY平均糖化血红蛋白分别为6.5%和6.1%,低于1型糖尿病的7.9%(P<0.0001)。
- 40%的HNF1B-MODY患者报告胰腺外症状。
临床怎么用
- 对于诊断年龄较大、C肽较高且糖化血红蛋白控制较好的年轻糖尿病患者,应警惕MODY可能,避免误分类为1型或2型糖尿病。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To characterize the initial presentation and clinical course of patients with hepatocyte nuclear factor (HNF) 4A‒ and HNF1B‒MODY in a multinational registry. DESIGN, SETTING, AND PARTICIPANTS: Within the Diabetes Patienten Verlaufsdokumentation (DPV) registry, 44 patients with HNF4A- and 35 patients with HNF1B-MODY were characterized and compared with patients <20 years old with type 1 diabetes (T1D)/type 2 diabetes (T2D). MAIN OUTCOME MEASURE: Clinical and laboratory parameters, therapy, metabolic control, and extrapancreatic symptoms in patients with HNF1B-MODY. RESULTS: Patients with both MODY types were significantly older than patients with T1D at diagnosis (HNF4A, 13.8 years, and HNF1B, 13.5 years, vs T1D, 8.8 years; P < 0.0001). Mean C-peptide at diagnosis was higher for HNF4A-MODY than for T1D (1.8 vs 0.9 ng/mL; P < 0.01); 36.4% of patients with HNF4A-MODY and 65.7% of patients with HNF1B-MODY were treated with insulin, whereas 20.5% and 8.6% received oral antidiabetics only (P < 0.05 and P < 0.01 vs T2D). At the most recent visit, glycated hemoglobin levels were lower in HNF4A- and HNF1B-MODY (mean, 6.5% and 6.1%) than in T1D (7.9%; P < 0.0001). In 40% of patients with HNF1B-MODY, extrapancreatic symptoms were reported. Several clinical predictors previously described to differentiate between MODY and T1D or T2D were revalidated by logistic regression analyses in this cohort. CONCLUSION: The DPV registry enabled us to precisely characterize phenotype and treatment in these two rare MODY types. Although phenotype of HNF4A- and HNF1B-MODY showed distinct differences from those of T1D and T2D, 38% of patients were initially misclassified as having T1D or T2D.
引用
- Warncke K, Kummer S, Raile K, et al. Frequency and Characteristics of MODY 1 (HNF4A Mutation) and MODY 5 (HNF1B Mutation): Analysis From the DPV Database. J Clin Endocrinol Metab. 2019. PMID: 30535056. doi:10.1210/jc.2018-01696
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。